Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.

“In today’s patient-centric healthcare system, genetic counselors play an integral role by empowering patients and physicians with data-driven genetic insights and personalized medical information to support critical healthcare decisions,” said Paul J. Diaz, president and CEO, Myriad Genetics. “We’re committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.”

On Saturday, Nov. 19 at 12:30 p.m. CT, Myriad will host a CEU symposium titled ‘How inclusion, accessibility, innovation and collaboration are shaping the future of precision medicine’, presented by Nicole Lambert, chief operating officer; Thomas Slavin, M.D., chief medical officer; Dale Muzzey, Ph.D., chief scientific officer; and Susan Manley, senior vice president of Medical Services. Myriad also will share a poster titled ‘Curation of pathogenic genome-wide copy number variants in a noninvasive prenatal screen (NIPS)’ by Sam Cox, Ph.D., senior clinical genomics scientist. Data will highlight how technological improvements now allow for the detection of copy number variants (CNVs) across the genome in NIPS.

Among the Myriad products highlighted in the company’s NSGC exhibit (#307) are:

  • MyRisk™ with RiskScore®, Myriad’s market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries. RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk. JCO Precision Oncology recently published a study1 that highlights the development and validation of RiskScore for women of all ancestries. The study examined data from more than 275,000 women of diverse ancestral backgrounds to validate the use of ancestry-informative genetic markers. Results showed the new method was more accurate for women of all ancestries.
  • Prequel® with AMPLIFY technology, a non-invasive prenatal screen (NIPS) that helps determine if a pregnancy is at increased risk for common chromosomal abnormalities regardless of ancestry or body mass index.
  • ForeSight®, a prenatal carrier screen to detect couples who are at risk of passing down serious inherited conditions.
  • Precise™ Oncology Solutions, a comprehensive suite of solutions offering streamlined testing and reporting for germline testing, tumor profiling and companion diagnostic options to guide cancer treatment decisions.

Myriad Live from NSGC
Myriad will conduct a series of livestreams from NSGC available on the company’s social channels – Facebook, LinkedIn and Twitter – including the following:

  • Fireside chat with Myriad Genetics CEO Paul J. Diaz
    Friday, Nov. 18: 12:15-12:30 p.m. CT
    Myriad Genetics’ Paul J. Diaz, president and CEO, and Susan Manley, LCGC, senior vice president of Medical Services, discuss Myriad’s transformation and growth initiatives and engagement with genetic counselors.
  • Advancing health equity in prenatal care
    Friday, Nov. 18: 1:00-1:15 p.m. CT
    Kira Dineen, MS, LCGC, CG(ASCP)CM, founder of the DNA Today Podcast and prenatal genetic counselor at Maternal Fetal Care PC, and Thomas Slavin, M.D., chief medical officer, Myriad Genetics, explore technology advancements that improve equity in prenatal care.
  • The inside scoop on NSGC’s 41st Annual Conference
    Friday, Nov. 18: 1:40-2:00 p.m. CT
    Melanie Hardy, MS, MS, CGC, Emory University and NSGC annual conference committee chair and Nicole Lambert, chief operating officer, Myriad Genetics, review key developments at the national conference with a focus on advancing the genetic counseling profession.
  • Straight talk from a NSGC first timer
    Friday, Nov. 18: 3:30-3:45 p.m. CT
    Kamille Clever, MS, CGC, Cleveland Clinic and Shelly Cummings, CGC, VP oncology medical affairs, Myriad Genetics, discuss navigating the NSGC conference and share initial impressions.
  • Precision medicine – Now and next
    Friday, Nov. 18: 4:00-4:20 p.m. CT
    Myriad Genetics’ Dale Muzzey, Ph.D., chief scientific officer and Katie Ziegler, regional medical specialist, share a view of new innovations and product advancements shaping the future of precision medicine.
  • Empowering women to take control of their breast health
    Friday, Nov. 18: 5:00-5:15 p.m. CT
    Laura Crandon, president and founder, Touch4Life and Gwen Turner, head of ESG, diversity, equity & inclusion, Myriad Genetics, discuss collaborative ways to help all women be active about breast health for life.

Special events for genetic counselors
Myriad Genetics will sponsor NSGC’s welcome reception for all genetic counselors who are first-time conference attendees, Wednesday, Nov. 16, 6:00-7:00 p.m. CT. Myriad also will host its 9th Annual Genetic Counselor Appreciation Event and fundraiser on Friday, Nov. 18, 7:30-11:30 p.m. CT, supporting Touch4Life; Eva’s Butterfly Wishes/National Organization for Rare Disorders; and CONNECTUS Health.

1 Hughes et al. JCO Precision Oncology 2022 (

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved. 

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s commitment to increase collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations. These “forward-looking statements” are based on management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:
Megan Manzari
(385) 318-3718
Investor Contact:
Matt Scalo
(801) 584-3532